Biosimilar antibodies can be used to study the biological effects of a drug without the need for expensive pharmaceutical-grade therapeutic products. They can be used in a variety of research applications, including functional tests, flow cytometry, ELISA, immunohistochemistry, pharmacokinetic tests, and others. At present, the biological functions of monoclonal antibody drugs are mainly reflected in three aspects: inhibition of tumor survival key molecules, tumor immune intrinsic and adaptive activation, and antibody conjugated cytotoxic drugs. Monoclonal antibody targets are mainly focused on HERTNF, CD20, PD-1/L1, VEGF and CD3.
Biosimilar antibodies are developed with recombinant antibody expression technology using the same sequence as the therapeutic antibody and ensure specific binding to the same targeted molecule. The high quality biosimilar antibody products are usually produced in well-characterized cell lines with a long history of producing therapeutics. Here, I will present four biosimilar monoclonal antibodies commonly used in research.
Rituximab is a murine/human chimeric monoclonal antibody with IgG1/κ isotype directed against the CD20 antigen expressed by B cells used for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL), and rheumatoid arthritis.
Trastuzumab is a humanized IgG1/κ monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and is used for the treatment of HER2-positive early or metastatic breast cancer.
Adalimumab is a fully human IgG1/κ anti-tumour necrosis factor α (anti-TNFα) monoclonal antibody that prevents the interaction of TNFα with its receptors, thereby interfering with the inflammatory signalling central to chronic autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease.
Infliximab is a chimeric recombinant monoclonal antibody with IgG1/κ isotype that targets TNFα and was the first TNFα inhibitors used to treat chronic inflammation. It is used for the treatment of several conditions, including inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis.
Alpha Lifetech Inc. offers over 700 biosimilar antibody products against various targets. Our product list covers Adalimumab Biosimilar, Bevacizumab Biosimilar, Dupilumab Biosimilar, Eptinezumab Biosimilar, Rituximab Biosimilar, Teprotumumab Biosimilar, etc. Based on our professional antibody R&D team and rich experience in antibody expression production, we are confident in the quality of our biosimilar antibody products and strive to accelerate your research. Our biosimilar antibodies are available in a variety of sizes from ug to g level according to customers' demand. If there is no stock, it can be quickly expressed within 2-3 weeks.
Our biosimilar antibodies are of exceptional quality and consistency. Whether you order our product or speak to one of our technical service representatives, our staff is committed to providing professional support! For more information, please contact us and our technical support team will get back to you as soon as possible.